Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Biocytogen Signs Option to Out-License Three Antibodies to ADC Therapeutics

publication date: Nov 29, 2022

Biocytogen Pharma (Beijing)  signed an option agreement with Switzerland’s ADC Therapeutics granting ADC a license to evaluate Biocytogen’s antibodies against three tumor targets. ADC will have an option to license any of the antibodies for global ADC development and commercialization. Biocytogen is using its proprietary platform to develop first-in-class and/or best-in-class antibody candidates for more than 1000 targets, So far, the effort has resulted in 28 drug co-development and 16 RenMiceTM licensing agreements with drug development companies, including several multinational pharmas. More details...

Stock Symbol: (HK: 02315)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital